...
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >Lambert-Eaton Myasthenic syndrome: early diagnosis is key
【24h】

Lambert-Eaton Myasthenic syndrome: early diagnosis is key

机译:Lambert-Eaton重症肌无力综合征:早期诊断是关键

获取原文
           

摘要

Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular transmission with distinctive pathophysiological, clinical, electrophysiological and laboratory features. There are two forms of LEMS. The paraneoplastic (P-LEMS) form is associated with a malignant tumor that is most frequently a small cell lung carcinoma (SCLC), and the autoimmune (A-LEMS) form is often related to other dysimmune diseases. Approximately 90% of LEMS patients present antibodies against presynaptic membrane P/Q-type voltage-gated calcium channels (VGCC). These antibodies are directly implicated in the pathophysiology of the disorder, provoke reduced acetylcholine (ACh) at the nerve terminal and consequently lead to muscle weakness. LEMS is clinically characterized by proximal muscle weakness, autonomic dysfunction and areflexia. In clinically suspected cases, diagnoses are confirmed by serological and electrodiagnostic tests. The detection of P/Q-type VGCC antibodies is supportive when there is clinical suspicion but should be carefully interpreted in the absence of characteristic clinical or electrodiagnostic features. Typical electrodiagnostic findings (ie, reduced compound motor action potentials (CMAPs), significant decrements in the responses to low frequency stimulation and incremental responses after brief exercise or high-frequency stimulation) reflect the existence of a presynaptic transmission defect and are key confirmatory criteria. Diagnosis requires a high level of awareness and necessitates the initiation of a prompt screening and surveillance process to detect and treat malignant tumors. In clinically affected patients without cancer and after cancer treatment, symptomatic treatment with 3,4-diaminopyridine or immunosuppressive agents can significantly improve neurologic symptoms and the quality of life. We present a detailed review of LEMS with special emphasis on the pathophysiological mechanisms, clinical manifestation and diagnostic procedure.
机译:Lambert-Eaton重症肌无力综合症(LEMS)是一种罕见的神经肌肉传递疾病,具有独特的病理生理,临床,电生理和实验室特征。 LEMS有两种形式。副肿瘤(P-LEMS)形式与恶性肿瘤有关,恶性肿瘤通常是小细胞肺癌(SCLC),而自身免疫(A-LEMS)形式通常与其他免疫异常疾病有关。大约90%的LEMS患者呈现针对突触前膜P / Q型电压门控钙通道(VGCC)的抗体。这些抗体直接与疾病的病理生理有关,在神经末梢引起乙酰胆碱(ACh)减少,从而导致肌肉无力。 LEMS的临床特征是近端肌肉无力,自主神经功能紊乱和反射减弱。在临床可疑病例中,可通过血清学和电诊断检查确认诊断。当有临床怀疑时,P / Q型VGCC抗体的检测是支持的,但在缺乏特征性临床或电诊断特征时应仔细解释。典型的电诊断发现(即,降低的复合运动动作电位(CMAP),对低频刺激的反应显着下降以及短暂运动或高频刺激后的增量反应)反映出突触前传递缺陷的存在,并且是关键的确认标准。诊断需要很高的意识,并且有必要启动迅速的筛查和监视过程以检测和治疗恶性肿瘤。在没有癌症且在接受癌症治疗后受临床影响的患者中,使用3,4-二氨基吡啶或免疫抑制剂进行对症治疗可以显着改善神经系统症状和生活质量。我们对LEMS进行了详细的回顾,特别着重于病理生理机制,临床表现和诊断程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号